Zacks Research Issues Positive Forecast for Maximus Earnings

Maximus, Inc. (NYSE:MMSFree Report) – Investment analysts at Zacks Research upped their FY2026 EPS estimates for Maximus in a research note issued on Wednesday, May 27th. Zacks Research analyst Team now forecasts that the health services provider will post earnings per share of $8.41 for the year, up from their prior forecast of $8.34. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Maximus’ current full-year earnings is $8.40 per share. Zacks Research also issued estimates for Maximus’ Q4 2026 earnings at $2.29 EPS, Q1 2027 earnings at $1.94 EPS, Q3 2027 earnings at $2.33 EPS, Q4 2027 earnings at $1.95 EPS, FY2027 earnings at $8.43 EPS, Q1 2028 earnings at $2.02 EPS and Q2 2028 earnings at $2.22 EPS.

Maximus (NYSE:MMSGet Free Report) last announced its earnings results on Thursday, May 7th. The health services provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Maximus had a net margin of 7.02% and a return on equity of 25.10%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter last year, the firm earned $2.01 earnings per share. Maximus’s quarterly revenue was down 4.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 8.250-8.550 EPS.

A number of other brokerages also recently weighed in on MMS. Weiss Ratings downgraded shares of Maximus from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 20th. Wall Street Zen downgraded shares of Maximus from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Two analysts have rated the stock with a Hold rating, According to MarketBeat.com, Maximus currently has a consensus rating of “Hold”.

View Our Latest Research Report on Maximus

Maximus Price Performance

Shares of NYSE MMS opened at $61.97 on Thursday. Maximus has a twelve month low of $56.92 and a twelve month high of $100.00. The firm has a fifty day simple moving average of $64.84 and a 200 day simple moving average of $77.58. The company has a market capitalization of $3.26 billion, a PE ratio of 9.28 and a beta of 0.60. The company has a quick ratio of 2.21, a current ratio of 2.21 and a debt-to-equity ratio of 0.87.

Maximus Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, May 15th. Maximus’s payout ratio is 19.76%.

Insiders Place Their Bets

In other Maximus news, Director Jan Madsen sold 742 shares of Maximus stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total value of $53,609.50. Following the completion of the sale, the director directly owned 20,795 shares of the company’s stock, valued at approximately $1,502,438.75. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in MMS. JPMorgan Chase & Co. boosted its holdings in Maximus by 19.8% during the third quarter. JPMorgan Chase & Co. now owns 200,331 shares of the health services provider’s stock worth $18,304,000 after purchasing an additional 33,136 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Maximus by 2.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,869,573 shares of the health services provider’s stock worth $170,812,000 after purchasing an additional 36,989 shares during the last quarter. Divisadero Street Capital Management LP boosted its holdings in Maximus by 93.5% during the third quarter. Divisadero Street Capital Management LP now owns 183,872 shares of the health services provider’s stock worth $16,800,000 after purchasing an additional 88,872 shares during the last quarter. WINTON GROUP Ltd purchased a new position in Maximus during the third quarter worth about $6,208,000. Finally, Assenagon Asset Management S.A. purchased a new position in Maximus during the fourth quarter worth about $15,673,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

About Maximus

(Get Free Report)

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.

Recommended Stories

Earnings History and Estimates for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.